CRSP
Price
$44.02
Change
-$0.60 (-1.34%)
Updated
Dec 18, 11:36 AM (EDT)
62 days until earnings call
EDIT
Price
$1.48
Change
-$0.04 (-2.63%)
Updated
Dec 18, 11:58 AM (EDT)
70 days until earnings call
Ad is loading...

CRSP vs EDIT

Header iconCRSP vs EDIT Comparison
Open Charts CRSP vs EDITBanner chart's image
CRISPR Therapeutics AG
Price$44.02
Change-$0.60 (-1.34%)
Volume$357
CapitalizationN/A
Editas Medicine
Price$1.48
Change-$0.04 (-2.63%)
Volume$3.16K
CapitalizationN/A
CRSP vs EDIT Comparison Chart
Loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CRSP vs. EDIT commentary
Dec 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRSP is a Hold and EDIT is a Hold.

COMPARISON
Comparison
Dec 18, 2024
Stock price -- (CRSP: $44.63 vs. EDIT: $1.52)
Brand notoriety: CRSP and EDIT are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CRSP: 80% vs. EDIT: 112%
Market capitalization -- CRSP: $3.81B vs. EDIT: $125.47M
CRSP [@Biotechnology] is valued at $3.81B. EDIT’s [@Biotechnology] market capitalization is $125.47M. The market cap for tickers in the [@Biotechnology] industry ranges from $486.73B to $0. The average market capitalization across the [@Biotechnology] industry is $2.66B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CRSP’s FA Score shows that 0 FA rating(s) are green whileEDIT’s FA Score has 1 green FA rating(s).

  • CRSP’s FA Score: 0 green, 5 red.
  • EDIT’s FA Score: 1 green, 4 red.
According to our system of comparison, EDIT is a better buy in the long-term than CRSP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CRSP’s TA Score shows that 2 TA indicator(s) are bullish while EDIT’s TA Score has 4 bullish TA indicator(s).

  • CRSP’s TA Score: 2 bullish, 7 bearish.
  • EDIT’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, EDIT is a better buy in the short-term than CRSP.

Price Growth

CRSP (@Biotechnology) experienced а -8.32% price change this week, while EDIT (@Biotechnology) price change was -27.62% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -4.84%. For the same industry, the average monthly price growth was +1.08%, and the average quarterly price growth was +4.66%.

Reported Earning Dates

CRSP is expected to report earnings on Feb 18, 2025.

EDIT is expected to report earnings on Feb 26, 2025.

Industries' Descriptions

@Biotechnology (-4.84% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CRSP($3.81B) has a higher market cap than EDIT($125M). CRSP YTD gains are higher at: -28.706 vs. EDIT (-84.995).
CRSPEDITCRSP / EDIT
Capitalization3.81B125M3,047%
EBITDAN/A-222.63M-
Gain YTD-28.706-84.99534%
P/E RatioN/AN/A-
RevenueN/A61.8M-
Total CashN/A265M-
Total DebtN/A38.5M-
FUNDAMENTALS RATINGS
CRSP vs EDIT: Fundamental Ratings
CRSP
EDIT
OUTLOOK RATING
1..100
682
VALUATION
overvalued / fair valued / undervalued
1..100
63
Fair valued
15
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9398
PRICE GROWTH RATING
1..100
8097
P/E GROWTH RATING
1..100
83100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

EDIT's Valuation (15) in the Biotechnology industry is somewhat better than the same rating for CRSP (63). This means that EDIT’s stock grew somewhat faster than CRSP’s over the last 12 months.

EDIT's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CRSP (100). This means that EDIT’s stock grew similarly to CRSP’s over the last 12 months.

CRSP's SMR Rating (93) in the Biotechnology industry is in the same range as EDIT (98). This means that CRSP’s stock grew similarly to EDIT’s over the last 12 months.

CRSP's Price Growth Rating (80) in the Biotechnology industry is in the same range as EDIT (97). This means that CRSP’s stock grew similarly to EDIT’s over the last 12 months.

CRSP's P/E Growth Rating (83) in the Biotechnology industry is in the same range as EDIT (100). This means that CRSP’s stock grew similarly to EDIT’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CRSPEDIT
RSI
ODDS (%)
Bearish Trend 1 day ago
74%
Bullish Trend 1 day ago
87%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
76%
Bullish Trend 1 day ago
79%
Momentum
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 6 days ago
78%
MACD
ODDS (%)
Bearish Trend 1 day ago
77%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
82%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 1 day ago
78%
Declines
ODDS (%)
Bearish Trend 6 days ago
84%
Bearish Trend 6 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
77%
Bullish Trend 1 day ago
85%
Aroon
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
CRSP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
EDIT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME31.261.82
+6.18%
GameStop Corp
TSLA479.8616.84
+3.64%
Tesla
AAPL253.482.44
+0.97%
Apple
BTC.X106140.600000110.890625
+0.10%
Bitcoin cryptocurrency
SPY604.29-2.50
-0.41%
SPDR® S&P 500® ETF Trust

CRSP and

Correlation & Price change

A.I.dvisor indicates that over the last year, CRSP has been closely correlated with BEAM. These tickers have moved in lockstep 72% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRSP jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CRSP
1D Price
Change %
CRSP100%
+0.88%
BEAM - CRSP
72%
Closely correlated
-1.21%
PRME - CRSP
63%
Loosely correlated
-3.00%
NTLA - CRSP
62%
Loosely correlated
-1.87%
RXRX - CRSP
61%
Loosely correlated
-4.30%
EDIT - CRSP
61%
Loosely correlated
+2.70%
More

EDIT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EDIT has been loosely correlated with NTLA. These tickers have moved in lockstep 62% of the time. This A.I.-generated data suggests there is some statistical probability that if EDIT jumps, then NTLA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EDIT
1D Price
Change %
EDIT100%
+2.70%
NTLA - EDIT
62%
Loosely correlated
-1.87%
CRSP - EDIT
59%
Loosely correlated
+0.88%
BEAM - EDIT
56%
Loosely correlated
-1.21%
PRME - EDIT
51%
Loosely correlated
-3.00%
ALLO - EDIT
50%
Loosely correlated
+0.49%
More